Shares of United Therapeutics Co. (NASDAQ:UTHR) have received an average recommendation of “Hold” from the twelve ratings firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $137.57.

UTHR has been the subject of several research analyst reports. Cowen set a $106.00 price objective on shares of United Therapeutics and gave the stock a “hold” rating in a research report on Thursday. BidaskClub cut shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, September 24th. HC Wainwright set a $95.00 price objective on shares of United Therapeutics and gave the stock a “hold” rating in a research report on Monday, August 13th. Barclays restated a “sell” rating and issued a $100.00 price objective on shares of United Therapeutics in a research report on Thursday, August 2nd. Finally, Credit Suisse Group cut shares of United Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 8th.

Shares of UTHR traded up $3.49 on Friday, hitting $119.80. The company’s stock had a trading volume of 6,707 shares, compared to its average volume of 412,488. The company has a market capitalization of $4.91 billion, a P/E ratio of 11.01, a PEG ratio of 26.10 and a beta of 1.23. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.32 and a quick ratio of 4.05. United Therapeutics has a fifty-two week low of $100.57 and a fifty-two week high of $152.55.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 EPS for the quarter, missing the consensus estimate of $3.23 by ($0.81). The business had revenue of $412.70 million during the quarter, compared to analyst estimates of $378.22 million. United Therapeutics had a return on equity of 25.24% and a net margin of 31.73%. The firm’s revenue was down 7.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.69 earnings per share. On average, sell-side analysts anticipate that United Therapeutics will post 14.28 EPS for the current fiscal year.

In related news, Director Christopher Causey sold 810 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $119.00, for a total value of $96,390.00. Following the completion of the transaction, the director now owns 1,555 shares in the company, valued at approximately $185,045. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.20% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Globeflex Capital L P bought a new stake in shares of United Therapeutics during the 3rd quarter valued at $192,000. Advisor Partners LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at $201,000. Sun Life Financial INC bought a new stake in shares of United Therapeutics during the 2nd quarter valued at $198,000. Unison Advisors LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at $224,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at $229,000. Hedge funds and other institutional investors own 95.14% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Article: How Do You Make Money With Penny Stocks?

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.